Relacorilant pour le traitement du syndrome de Cushing endogène : une étude de sécurité

This study focuses on the continued use of Relacorilant (CORT125134), a powerful and selective glucocorticoid receptor (GR) antagonist. The purpose is to treat patients who have previously participated in a study involving Relacorilant for Endogenous Cushing Syndrome, a condition where the body produces too much cortisol. The study aims to provide ongoing treatment to those who have shown improvement and could benefit from further use of Relacorilant. The importance lies in potentially offering a long-term solution for managing the signs and symptoms of this syndrome. Participants in this study will continue to take Relacorilant once daily, as long as they are benefiting from the treatment, as determined by the investigator. The dose may be adjusted based on the individual's response and tolerability. The primary outcome measured is the long-term safety of Relacorilant, specifically the number of participants who experience treatment-emergent adverse events (TEAEs). These events are assessed using a standardized system called CTCAE v4.0.